Top

Published in:

01-12-2024 | PSA Screening | Letter to the Editor

Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening

Author: Takeshi Takahashi

Published in: World Journal of Urology | Issue 1/2024

Excerpt

The article is a study of PI-RADS, a tool to standardize MRI findings in PSA-based prostate cancer screening [1]. The theoretical background of these attempts to use MRI is that the harm of overdiagnosis can be mitigated by efficiently detecting clinically significant cancers and avoiding definitive treatment for clinically insignificant cancers. In fact, several hypotheses underlie this. …

Kwe J, Baunacke M, Boehm K, Platzek I, Thomas C, Borkowetz A (2024) PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions. World J Urol 42(1):84. https://doi.org/10.1007/s00345-024-04776-xCrossRefPubMedPubMedCentral

Young RH, Eble JN (2019) The history of urologic pathology: an overview. Histopathology 74(1):184–212. https://doi.org/10.1111/his.13753CrossRefPubMed

Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2005) ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228–1242. https://doi.org/10.1097/01.pas.0000173646.99337.b1CrossRefPubMed

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the U.S. preventive services task force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17–05229-EF-1.

Catalona WJ (2018) Prostate cancer screening. Med Clin North Am 102(2):199–214. https://doi.org/10.1016/j.mcna.2017.11.001CrossRefPubMedPubMedCentral

Hamdy FC, Donovan JL, Lane JA et al (2023) ProtecT Study Group. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388(17):1547–1558. https://doi.org/10.1056/NEJMoa2214122CrossRefPubMed

United States Preventive Service Task Force, Final Recommendation Statement, Prostate Cancer Screening. Updated 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening Accessed 01 Jan 2024.

Takahashi T (2023) Prostate-specific antigen screening should not be covered by publicly funded health insurance. JAMA Oncol 9(6):867–868. https://doi.org/10.1001/jamaoncol.2023.0254CrossRefPubMed

Takahashi T (2023) Prebiopsy risk calculators, such as MRI and prostate cancer screening, are early-phase clinical trials. Radiology 309(2):e231177. https://doi.org/10.1148/radiol.231177CrossRefPubMed

Title: Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening
Author: Takeshi Takahashi
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: PSA Screening
Prostate Cancer
Prostate Cancer
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-024-04905-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Analysis of urinary retention after endoscopic prostate enucleation and its subsequent impact on surgical outcomes

Infection risk reduction with povidone-iodine rectal disinfection prior to transrectal prostate biopsy: an updated systematic review and meta-analysis

Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score-matched analysis

Do alpha blockers reduce the risk of urinary retention post-transperineal prostate biopsy? A systematic narrative review

Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma

Cost-effectiveness analysis of prostate cancer screening and MRI